China SXT Pharmaceuticals (STU:2RY1) FCF Margin %: -279.78% (As of Sep. 2025)


STU:2RY1 China SXT Pharmaceuticals Inc STU:2RY1
26 GF Score
Price €384.00
! 5 Warning Signs
View Full Analysis

What is China SXT Pharmaceuticals FCF Margin %?

China SXT Pharmaceuticals STU:2RY1 26 FCF Margin % is -279.78% as of Sep. 2025. GuruFocus rates STU:2RY1 with a GF Score™ of 26/100. The stock has 5 warning signs investors should review. Among 958 Drug Manufacturers companies, China SXT Pharmaceuticals ranks worse than 93.95% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. China SXT Pharmaceuticals's Free Cash Flow for the six months ended in Sep. 2025 was €-1.49 Mil. China SXT Pharmaceuticals's Revenue for the six months ended in Sep. 2025 was €0.53 Mil. Therefore, China SXT Pharmaceuticals's FCF Margin % for the quarter that ended in Sep. 2025 was -279.78%.

As of today, China SXT Pharmaceuticals's current FCF Yield % is -25.51%.

The historical rank and industry rank for China SXT Pharmaceuticals's FCF Margin % or its related term are showing as below:

STU:2RY1' s FCF Margin % Range Over the Past 10 Years
Min: -174.87   Med: -5.29   Max: 12.38
Current: -174.87

During the past 9 years, the highest FCF Margin % of China SXT Pharmaceuticals was 12.38%. The lowest was -174.87%. And the median was -5.29%.

STU:2RY1's FCF Margin % is ranked worse than
93.95% of 958 companies
in the Drug Manufacturers industry
Industry Median: 2.445 vs STU:2RY1: -174.87

China SXT Pharmaceuticals FCF Margin % Related Terms

China SXT Pharmaceuticals FCF Margin % Historical Data

* Premium members only.

The historical data trend for China SXT Pharmaceuticals's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China SXT Pharmaceuticals FCF Margin % Chart

China SXT Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
FCF Margin %
Get a 7-Day Free Trial Premium Member Only -29.50 7.91 -7.71 -100.34 -134.84

China SXT Pharmaceuticals Semi-Annual Data
Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -61.63 -136.26 -163.72 -108.42 -279.78

STU:2RY1 vs YCBD, CVSI, INM: FCF Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, China SXT Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

China SXT Pharmaceuticals FCF Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China SXT Pharmaceuticals's FCF Margin % distribution charts can be found below:

* The bar in red indicates where China SXT Pharmaceuticals's FCF Margin % falls into.


STU:2RY1
26GF Score
China SXT Pharmaceuticals Inc STU:2RY1
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

China SXT Pharmaceuticals FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

China SXT Pharmaceuticals's FCF Margin for the fiscal year that ended in Mar. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Mar. 2025 )/Revenue (A: Mar. 2025 )
=-2.171/1.61
=-134.84 %

China SXT Pharmaceuticals's FCF Margin for the quarter that ended in Sep. 2025 is calculated as

FCF Margin=Free Cash Flow (Q: Sep. 2025 )/Revenue (Q: Sep. 2025 )
=-1.494/0.534
=-279.78 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -279.78% mean?
China SXT Pharmaceuticals (STU:2RY1) has a FCF Margin % of -279.78% as of Sep. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on China SXT Pharmaceuticals and its competitors. According to the industry distribution chart, China SXT Pharmaceuticals ranks #900 out of 958 companies in the Drug Manufacturers industry, placing it in the top 93.9%.
Is China SXT Pharmaceuticals' FCF Margin % too high?
China SXT Pharmaceuticals' current FCF Margin % is -279.78%. Based on the distribution chart, China SXT Pharmaceuticals ranks #900 out of 958 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, China SXT Pharmaceuticals has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does China SXT Pharmaceuticals' FCF Margin % compare to YCBD and CVSI?
According to the Drug Manufacturers industry distribution chart, China SXT Pharmaceuticals ranks #900 out of 958 companies for FCF Margin %. This places China SXT Pharmaceuticals in the lower half of its industry. The industry median FCF Margin % is 2.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.45, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on China SXT Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China SXT Pharmaceuticals's current FCF Margin % is -279.78%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China SXT Pharmaceuticals stock overvalued right now?
China SXT Pharmaceuticals (STU:2RY1) has a current FCF Margin % of -279.78%. The current FCF Margin % is -279.78%. China SXT Pharmaceuticals' overall GF Score™ is 26/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For China SXT Pharmaceuticals (STU:2RY1), the current FCF Margin % is -279.78% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

China SXT Pharmaceuticals Business Description

Other Exchanges SXTC:USA
Address No. 178 Taidong Road North, Jiangsu, Taizhou, CHN, 225300
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.
26GF Score

Get the complete analysis for STU:2RY1

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€384.00
Price